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Prevalence and determinants of erectile dysfunction in hemodi- Erectile dysfunction (ED) is estimated to affect be-
alysis patients. tween 10- and 30-million men in the United States [1].
Background. The prevalence of erectile dysfunction (ED) However, the prevalence of ED among patients withamong patients with end-stage renal disease (ESRD) is not
end-stage renal disease (ESRD) is not known. Severalknown.
cross-sectional studies in hemodialysis (HD) patientsMethods. A cross-sectional study was conducted to deter-
mine the prevalence of ED among a community-based hemodi- have attempted to measure the prevalence of ED in
alysis (HD) population using a two-stage cluster random sam- small convenience samples [2]. Perhaps because of varied
pling design. The presence and severity of ED were assessed definitions of ED, the estimates of its prevalence haveamong 302 ESRD patients using the self-administered Interna-
ranged from 41 to 93%.tional Index of Erectile Function-5 (IIEF-5). Logistic regres-
There are many reasons to expect a high prevalencesion was used to examine and test associations between ED
and other medical conditions. of ED in HD populations. A number of the illnesses,
Results. The prevalence of any level of ED was 82% (95% such as atherosclerosis, heart disease, diabetes, and hy-
CI, 76 to 87%) for all HD subjects. The prevalence of severe
pertension, that are associated with ED also tend to beED was 45% (CI, 36 to 55%). Subjects younger than 50 years
common among patients with ESRD. Medications fre-had a prevalence of ED of 63% (CI, 53 to 71%), while in
subjects 50 years or older, it was 90% (CI, 84 to 94%). A quently used in the setting of renal disease have also been
multivariable analysis demonstrated increasing age (50 to 59, associated with ED, including several diuretics, anti-
OR 5 2.04, 95% CI, 1.3 to 3.1; 60 to 69, OR 5 5.5, 95% CI, hypertensives, antidepressants, and H2 antagonists.1.9 to 15.6) and diabetes (OR 5 2.0, 95% CI, 1.2 to 3.3) to be
Despite the suspected association of ED and ESRDindependently associated with the presence of any level of
and the impact that ED might have on the quality ofED. However, neither the subjects’ age nor history of diabetes
predicted the severity of ED among subjects with ED. The life of these patients, the prevalence of ED in those with
use of angiotensin-converting enzyme inhibitors (ACEIs) was ESRD has not been well characterized. An accurate
inversely associated with ED (OR 5 0.41, 95% CI, 0.17 to
measure of the prevalence of ED in ESRD patients using0.98). Poor functional status (Karnofsky score or the Index of
newer, standardized, and validated diagnostic instru-Physical Impairment) was not associated with ED.
Conclusions. ED is extremely prevalent among HD pa- ments has not been completed. With the availability of
tients. Increasing age, diabetes, and nonuse of ACEIs were newer effective therapies for ED, a better understanding
associated with higher prevalence of ED. The high prevalence of the prevalence and determinants of ED in HD patientsof ED was seen even among patients with good functional
should be a useful guide to medical practice. We reportstatus.
the findings of a population-based study of the preva-
lence of ED among a representative sample of commu-
nity-based patients receiving chronic HD.
METHODS
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the area, we used a two-stage cluster sampling design quested each patient’s primary nurse to evaluate their
functional status at the time of data collection. The scaleto obtain a study sample from which population-based
inferences could be made [3]. In the first stage, 16 HD ranges from 0 (dead) in 10-point increments to 100 (nor-
mal with no complaints). Each primary nurse was givenfacilities were randomly selected from all 51 facilities in
the area, with the probability of each facility’s inclusion written instructions on what each 10-point increment
meant with regard to functional ability. The nurses werebeing set approximately proportional to its size, as mea-
sured by its number of dialysis stations. In the second unaware of the patients’ response to the IIEF.
The Index of Co-Existing Disease (ICED) is a pre-stage, 20 subjects who met the eligibility criteria were
randomly selected from each chosen facility. Subjects viously validated instrument that classifies subjects with
ESRD on a four-point scale based on the presence andwere excluded if they were cognitively impaired or spoke
no English. Refusals were replaced with alternate sub- severity of 19 medical conditions and 11 physical impair-
ments (abstract; Greenfield et al, Clin Sci 35:346A, 1987).jects until 20 individuals from each facility were enrolled.
Using this sampling scheme, larger facilities had a higher These two components are summarized in the Index
of Disease Severity (IDS) and the Index of Physicalprobability of being selected, but eligible individual pa-
tients had an approximately equal probability of selec- Impairment (IPI). The IDS reflects the severity of each
of a selected list of 19 disease categories. The diseasetion into the study.
This study was approved by the University of Pennsyl- categories are rated using an explicit list of symptoms,
signs, and diagnostic tests indicating the presence andvania Institutional Review Board and the review boards
of the clinical centers. increasing severity of each identified condition. Level 1
characterizes a condition with little or no morbidity.
Data collection Level 2 is a symptomatic controlled disease. Level 3 is
an uncontrolled disease with moderate or severe mani-Sexual function. Each subject completed a self-admin-
istered five-item validated questionnaire [4], the IIEF-5, festations. Level 4 refers to an uncontrolled life-threaten-
ing disease (not appropriate for outpatients). The IPI iswhich is an abridged version of the 15-item International
Index of Erectile Function [5], which is commonly known intended to act as a snapshot of the impact of all of the
conditions on the patients’ functional ability where levelas the Sexual Health Inventory for Men (SHIM). The five
items included in the abbreviated IIEF-5 address the 0 is normal function, level 1 is mild to moderate impair-
ment, and level 2 is serious to severe impairment. TheNational Institutes of Health’s definition of ED, discrimi-
nate well between men with and without ED, and reflect IDS and IPI are combined to yield a single ICED score.
Higher scores reflect greater severity of disease or im-the severity of ED [4]. Subjects’ ED was measured and
categorized according to severity using a five-level ordinal pairment.
scale based on their score on the IIEF-5. A cutoff score
Statistical methodsof 21 (range of scores of 5 to 25) was used to define ED.
Subjects with scores of 21 or less were considered to have Our analyses sought to estimate the frequency or prev-
alence of ED in the HD population in metropolitanED. ED was also classified likewise into five validated
severity levels, ranging from none (22–25), mild (17–21), Philadelphia and to identify the associations of various
conditions with ED in that population. Because of themild/moderate (12–16), moderate (8–11), through severe
(5–7). Subjects also rated their ED on a supplemental two-stage sampling design, all prevalence estimates ac-
counted for (1) the somewhat unequal probabilities ofsingle-item scale from the Massachusetts Male Aging
Study as not impotent, minimally impotent, moderately selection of individual subjects in facilities of varying
size and (2) the clustered sampling, which affected theimpotent, and completely impotent, according to the
ability to always, usually, sometimes, or never achieve and variability of estimates [3]. To account for unequal selec-
tion probabilities, weighted estimation methods werekeep an erection good enough for sexual intercourse [6].
Comorbidity and functional status. Medical and demo- used [3], with each subject’s weight inversely propor-
tional to his probability of selection into the study. Thegraphic data were obtained for each subject from abstrac-
tion of dialysis records. Medical data collected included probability of selection into the study was the probability
of selecting a given dialysis unit times the probability ofmeasures of health status, time on dialysis, comorbid
conditions, laboratory studies such as hemoglobin, creat- selection of a given subject from that unit. Continuous
variables were described by their means and standardinine, albumin and parathyroid hormone, adequacy of
dialysis, compliance with dialysis, prior transplantation, errors and categorical variables by the proportion in each
category.and current medications.
The Karnofsky Performance Status was used to deter- Logistic regression (accounting for sampling design by
weighted estimation methods) was used to examine andmine the clinicians’ assessments of physical function [7].
The Karnofsky Performance Status score is a numeric test associations between ED and other conditions, ex-
cluding measures of quality of life [3]. First, the associa-representation of the patient’s functional ability. We re-
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Table 1. Prevalence and 95% CI of erectile dysfunction (ED) in all
subjects and by age
Prevalence % (CI)
ED severity All ,50 Years $50 Years
No ED 18 (13–24) 37 (29–47) 10 (6–17)
Mild 21 (16–27) 24 (18–31) 20 (14–27)
Mild/moderate 8 (5–12) 11 (5–23) 7 (5–11)
Moderate 8 (5–13) 7 (3–18) 8 (4–14)
Severe 45 (36–55) 21 (15–30) 56 (44–67)
tions between the presence of ED and demographic vari-
ables, prior comorbidities, medications, and laboratory
values were examined. Those variables in which the un-
Fig. 1. International Index of Erectile Function–5 (IIEF; h) versus theadjusted rate ratios had an associated P value of less
self report of impotence ( ), measured using the Massachusetts Male
than 0.1 were considered for inclusion in multivariable Aging Self-Report Question. The abbreviation ED is erectile dysfunc-
tion. Kappa 5 0.672.models. Then backward selection strategies were em-
ployed to fit the final models. These modeling activities
initially considered only baseline characteristics, includ-
ing demographics and comorbidity. Next, medications,
nephritis (2%), cystic disease (4%), and other (12%). Aexamined individually, were considered conditional on
history of cerebral vascular disease was present in 12%the baseline characteristics included in the previous step.
of subjects, while peripheral vascular disease was foundFinally, laboratory values and other physiologic parame-
in 27%. Nineteen percent had a history of lung disease,ters such as mean arterial pressure were added to the
including emphysema, chronic bronchitis, asthma, sleepmodel. For adding these variables, the same approach
apnea, or home oxygen requirement. Ten percent hadas described previously in this article was used. Analyses
a history of malignancy (other than basal cell carcinomawere performed using SAS version 6.12 (SAS Institute,
of the skin). A history of HIV infection was present inCary, NC, USA) and the survey estimation facilities of
2.5% of subjects.STATA, version 5 (Stata Corporation, College Station,
Fourteen percent of subjects had been on HD for sixTX, USA).
months to one year, 26% for one to two years, 33% for
two to four years, and 28% for more than four years.
RESULTS
Prevalence of EDUsing the methods described, 482 of 705 potentially
The prevalence and 95% CI for each of the five levelseligible men receiving HD in the 16 facilities were se-
of ED defined by the IIEF-5 for all subjects and stratifiedlected. Twenty-seven were excluded because of cognitive
by age group are shown in Table 1. The prevalence ofimpairment. Thirty-seven were not available. Twenty-
any level of ED was 82% (95% CI, 76 to 87%) for allfour were not eligible, and four had language barriers,
HD subjects. Forty-five percent (CI, 36 to 55%) of menleaving a total of 390 subjects who were asked to partici-
had severe ED. Older subjects ($50 years) were morepate. Of these, 88 (22.6%) subjects refused or did not
likely to experience ED [prevalence 90% (CI, 84 tocomplete the questionnaires. The individuals who re-
94%)], but younger patients (,50 years) also demon-fused did not differ from study subjects with regard to
strated a high prevalence [63% (CI, 53 to 71%)]. Usingage. The proportion less than 50 years of age was 23
the single item self-report supplemental scale, the pro-versus 25.4%, respectively. Because we did not have
access to the medical records of patients who refused portions reporting no ED, mild ED, moderate ED, and
severe ED were 22% (CI, 18 to 28%), 15% (CI, 9 toto participate, we were unable to compare them with
subjects with respect to other characteristics, such as race 24%), 17% (CI, 15 to 19%), and 46% (CI, 37 to 54%),
respectively, results very similar to those seen with theand diabetes.
The final study cohort was made up of 302 subjects. IIEF-5 self-report. Figure 1 represents the prevalence of
ED as measured by the IIEF and by the MassachusettsOne hundred seventy-two (59%) subjects were African
American. Nine patients (2.6%) were Hispanic. The Male Aging Study single item questionnaire.
Eighteen percent of subjects reported having beenmean 6 SD age was 59.5 6 15.5 years. Nearly all subjects
(97%) were hypertensive, and 39% had diabetes melli- treated for ED. Eight percent of subjects who scored
higher than 21 on the IIEF-5 had sought treatment fortus. The cause of ESRD was diabetes type I (17%),
diabetes type II (18%), hypertension (46%), glomerulo- ED compared with 21% of those who scored 21 or less
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Table 2. Association with presence of erectile dysfunctioin (ED)on the IIEF-5. Nineteen of the 302 subjects reported
having been treated with sildenafil. Two of these 19 were OR (95% CI) for
% with ED variable predictingnot identified as having ED by the IIEF questionnaire.
Variable (N) presence of ED
Age groupComorbidities and physical function
,50 61.2 (39) 1.00
No clear-cut association between functional status and 50–59 76.0 (50) 2.01 (1.24–3.26)
60–69 90.8 (58) 6.23 (2.06–18.82)ED was observed. The mean 6 SD ICED score was 2.11 6
701b 100.0 (83) ¥0.83. The distribution of subjects by score was 0 (0%),
Racea
1 (30%), 2 (29%), and 3 (41%). In unadjusted analyses, White 90.5 (97) 1.00
Black 77.1 (130) 0.36 (0.15–0.82)a higher ICED score was not significantly associated with
Other 81.3 (4) 0.46 (0.07–3.08)ED (P 5 0.44).
Duration on dialysis
The mean of the Karnofsky Index score was 81.3. The ,1 year 89.1 (33) 1.00
1–,2 years 85.1 (61) 0.70 (0.15–3.32)Karnofsky Index was marginally associated with ED (P 5
2–,4 years 83.2 (81) 0.60 (0.10–3.58)0.074). Patients with ED had lower scores when com-
41 years 75.3 (59) 0.37 (0.07–2.06)
pared with patients without ED (81, 95% CI, 76.5 to Hypertension
Yes 81.8 (223) 0.30 (0.03–3.27)85.5, vs. 86.5, 95% CI, 80.7 to 92.2).
No 93.8 (11) 1.00
DiabetesPredictors of ED
Yes 89.5 (94) 2.45 (1.61–3.72)
No 77.7 (140) 1.00Table 2 describes the different demographic variables
ACE inhibitorsstratified by the presence of ED along with the unad-
Yes 72.5 (61) 0.42 (0.18–0.96)
justed odds ratio. A history of prior kidney transplant No 86.4 (173) 1.00
Individual disease severitywas present in 20 men (7.0%), and this history was not
1 91.1 (6) 1.00statistically associated with ED (OR 5 0.55, 95% CI, 0.09
2 81.1 (143) 0.42 (0.04–4.89)
to 3.36, P 5 0.49). Forty-six (15.3%) subjects reported 3 83.8 (85) 0.51 (0.04–6.93)
Index of physical impairmentprostate problems, including history of prostatic cancer,
0 76.8 (83) 1.00prostatic surgery, or benign prostatic hypertrophy. A
1 87.6 (118) 2.13 (0.68–6.73)
history of prostatic disease was a statistically significant 2 81.9 (31) 1.37 (0.52–3.58)
Index of coexistent diseasepredictor of ED in unadjusted analyses (OR 5 2.99, 95%
1 78.2 (65) 1.00CI, 1.07 to 8.4, P 5 0.039).
2 85.8 (71) 1.68 (0.71–3.98)
Table 3 summarizes the subjects’ physiologic parame- 3 82.8 (97) 1.34 (0.61–2.92)
Cause of ESRDters stratified by ED. Subjects without ED had higher
Diabetes mellitus 89.9 (82) 1.00serum levels of parathyroid hormone (508.9 vs. 324.5,
Hypertension 78.3 (105) 0.41 (0.23–0.73)
P # 0.001) and higher creatinine (13.1 vs. 10.9, P 5 0.037) Other 75.9 (41) 0.36 (0.14–0.88)
Smoking statusin unadjusted analyses.
Never smoked 84.0 (59) 1.00The mean medications per patient were 2.69. No medi-
Smoked ,40 packs 78.5 (75) 0.70 (0.39–1.25)
cation or combination of medications was found to in- Smoked $40 packs 89.3 (72) 1.60 (0.51–5.05)
Alcohol useccrease the probability of ED in our population. The use
Doesn’t drink 83.6 (169) 1.00of angiotensin-converting enzyme inhibitors (ACEIs) was
,6 drinks/week 76.5 (44) 0.64 (0.20–2.05)
associated with a decreased prevalence of ED. Among 61 drinks/week 83.4 (14) 0.99 (0.31–3.12)
Karnofsky Index Mean (SE) patients with EDthose using an ACE inhibitor, 72.5% had ED, while
(per 10 unit increase) 80.98 (2.1) 0.81 (0.64–1.02)among those not using an ACEI, 86.4% had ED (OR 5
a Includes American Indian, Asian, and other/multiracial; there was no differ-0.42, 95% CI, 0.18 to 0.96). There was no evidence for
ence in estimates between models examining white versus non-white
confounding of this association between ACEIs and ED b All patients over 70 had ED
c Quantitation of ETOH consumption was done using the Khavari Alcoholby the presence of diabetes mellitus or by age group.
Test (36)
Patients with diabetes had a very similar exposure to
ACEIs (27%) as compared with patients without diabe-
tes (33%, P 5 0.38). The unadjusted associations be- Age, diabetes, and cause of ESRD were statistically
significantly associated with the presence of ED (Tabletween all medications and ED are presented in Table 4.
When subjects who were using ACE inhibitors were 5), while smoking status and alcohol intake were not.
Race was not found to be associated with ED after ad-compared to subjects who were on other antihyperten-
sive agents, the odds ratio of ED for ACE inhibitors justing for age. Subjects 50 to 59 years of age had an
odds of ED that was two (95% CI, 1.3 to 3.1) timescompared with other antihypertensive drugs was 0.44
(0.20 to 0.94, P 5 0.04). The result remained significant higher when compared with subjects less than 50 years
of age. For subjects between the ages of 60 to 69 years,after adjusting for age and diabetes, OR 5 0.42 (0.20 to
0.90, P 5 0.03). the odds ratio increased to 5.5 (95% CI, 1.9 to 15.6). All
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Table 3. Association of physiologic parameters with presence of erectile dysfunction (ED)
Patients with ED Patients without ED
Lab value units N 5 234 N 5 47
Hemoglobin mg/dL 11.5 (0.1) 11.3 (0.2)
Hematocrit % 35.5 (0.3) 34.8 (0.6)
Albumin g/dL 3.9 (0.04) 4.0 (0.05)
Kt/V 1.4 (0.03) 1.4 (0.06)
Urea reduction ratio % 69.1 (0.7) 66.6 (1.3)
Parathyroid hormone pg/dL 324.5 (29.8) 508.9 (61.6)
Creatinine mg/dL 10.9 (0.4) 13.1 (0.5)
Mean arterial pressure mm Hg 103.8 (0.9) 110.3 (2.1)
Data are mean (SE). For modeling purposes, each lab value was divided into categories as follows:
Hemoglobin (mg/dL): ,10, 10–11, 11–12, 121
Hematocrit (%): ,30, 30–33, 33–36, 361
Albumin (g/dL): ,3.5, 3.5–4, 41
Kt/V: ,1.2, 1.2–1.4, 1.41
URR (%): ,58, 58–65, 65–70, 701
PTH (pg/dL): ,400, 4001
Creatinine (mg/dL): ,8, 8–11, 11–13, 131
MAP (mm Hg): ,93, 93–106, 106–120, 1201
Table 4. Unadjusted analysis according to medication class
ED among patients ED among patients not OR (95% CI) for medication
Medication taking medication % (n) taking medication % (n) predicting presence of ED
Beta blockers 79.7 (67) 83.3 (167) 0.79 (0.32–1.95)
Diuretics 84.2 (19) 82.1 (215) 1.16 (0.27–5.07)
Central 100.0 (1) 82.2 (233) —
ACE inhibitors 72.5 (61) 86.4 (173) 0.42 (0.18–0.96)
Anticholinergics 94.0 (12) 81.7 (222) 3.53 (0.30–41.76)
Digoxin 92.8 (36) 80.6 (198) 3.13 (0.76–12.83)
Anxiolytic/antidepressant 92.5 (23) 81.3 (211) 2.85 (0.68–12.00)
Calcium channel blockers 80.5 (114) 84.0 (120) 0.79 (0.29–2.13)
Clonidine 78.2 (40) 83.1 (194) 0.73 (0.19–2.87)
Erythropoietin 81.5 (201) 88.2 (33) 0.59 (0.16–2.22)
Alpha blockers 92.3 (27) 81.3 (207) 2.77 (0.66–11.64)
ARB 72.4 (20) 83.3 (214) 0.53 (0.22–1.24)
Antihypertensives 80.7 (179) 87.6 (55) 0.59 (0.16–2.23)
Total number of medication classes
0 71.9 (10) 1.00
1 89.0 (37) 3.15 (0.66–15.14)
2 81.4 (62) 1.71 (0.35–8.24)
3 88.7 (68) 3.08 (0.78–12.16)
4 72.3 (35) 1.02 (0.16–6.65)
51 78.7 (22) 1.45 (0.30–7.10)
Abbreviations are: ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme; ED, erectile dysfunction.
subjects over 70 had ED. Subjects with diabetes had
twice the odds of having ED when compared with sub-
jects without diabetes (OR 5 2.0, 95% CI, 1.2 to 3.3).Table 5. Final multivariable logistic regression model
However, neither the subjects’ age nor history of diabe-
OR (95% CI) for variable
tes predicted the severity of ED among those with ED.Variable predicting presence of ED
Although unadjusted analyses suggested that a historyAge groupa
of prostate disease, mean arterial pressure, parathyroid,50 1.00
50–59 2.04 (1.34–3.13) hormone levels, and serum creatinine were significantly
60–69 5.49 (1.94–15.58) associated with ED, none were associated with ED after701 ¥
adjustment for age and diabetes and use of ACEI.Diabetes
Yes 1.97 (1.18–3.30)
No 1.00
ACE inhibitors DISCUSSION
Yes 0.41 (0.17–0.98)
No 1.00 Using population survey sampling techniques, we esti-
a All patients over 70 had ED mated the prevalence of ED among an urban HD popu-
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lation and found that over four fifths of male HD patients ciated with ED, a finding consistent with prior published
research. Commonly prescribed medications, particu-have some degree of ED. In 45% of the HD patients
studied, the ED was severe. Even among younger sub- larly diuretics, b blockers, and central a agonists, may
cause sexual dysfunction [27, 28]. A double-blind, ran-jects (,50 years), 63% reported some degree of ED, of
which one third was severe. Age and history of diabetes domized, cross-over design study comparing lisinopril to
atenolol evaluated subjects of 40 to 49 years of age withwere positively associated with the presence of ED, while
the use of ACEIs was associated with a lower risk of ED. newly diagnosed essential hypertension and without a
history of ED. The subjects in the lisinopril-treated groupA variety of definitions has been used to evaluate ED
in the HD population in 10 prior small studies. Eight of complained of sexual dysfunction symptoms elicited by
the study questionnaire less often than the subjectsthese 10 prior studies included fewer than 34 HD subjects
[2, 9–17]. Perhaps because of the varied definitions of treated with atenolol (3 vs. 17%, P , 0.05) [29]. It is
difficult, however, to determine whether the erectile im-ED and small sample size, the estimates of prevalence
ranged broadly from 41 to 93%. Levy defined ED as the pairment in controlled hypertension is due to the influ-
ence of the disease, medications, or both. Therefore,difficulty in getting or maintaining an erection [14]. Using
mail survey responses from 345 subjects, the investigator investigators have evaluated penile cavernous pressure
in normotensive animal models. Using this model, thefound that 70% of men had “some problem” with ED.
Using a definition of ED that was a “problem with erec- penile cavernous pressure response to nerve stimulation
is significantly impaired with propranolol and clonidine,tions which reduced sexual intercourse by 50% or more,”
Abram et al found a prevalence of 78% [17]. while captopril had no significant effect on these parame-
ters [30].Hemodialysis patients in our study demonstrated a
high prevalence of ED. Diabetes, increasing age, and The increased incidence of ED among hypertensive
patients in different therapeutic regimens is not a univer-the non-use of ACEIs were associated with the presence
of ED. Age was also correlated with ED in other studies, sal finding. In six randomized, blinded, prospective trials
in which 1251 men received placebo, 5 mg qd to 20 mgincluding the Massachusetts Male Aging Study [6, 18, 19].
Several prior studies have linked diabetes mellitus and bid enalapril, 2.5 to 10 mg qd amilodipine, and 6.25 to
25 mg of hydrochlorothiazide (HCTZ), bisoprolol 5 mgED. The Massachusetts Male Aging Study showed that
among patients with treated diabetes, the age-adjusted qd or a combination of 2.5 to 10 mg qd bisoprolol/HCTZ
for an average exposure duration of 6 to 14 weeks, ad-probability of “complete impotence” was 28% compared
with 9.6% in the general population [6]. Another popula- verse effects and symptoms were spontaneously volun-
teered by each subject. There was no difference betweention-based study of men aged 21 and older with 10 or
more years of diabetes taking insulin found an overall treatment modalities with respect to self-reported ED
(P 5 0.69), decrease in libido (P 5 0.97), or overallprevalence of ED of 20%. Among older subjects (over
age 43), the prevalence of ED was 47.1% [18]. sexual dysfunction (P 5 0.71) for 1251 men [31]. We
may have not been able to find a deleterious effect ofThe prevalence of ED was not associated with the
ICED score or functional status as measured by the the use of b blockers or diuretics due to a small subgroup
sample size. There were only 19 patients on diureticsKarnofsky score. The mean ICED score of 1.9 obtained
in some other large multicenter prospective dialysis trials and 67 subjects on b blockers.
The correlation of 0.672 between the IIEF in this studywas similar to the results observed in this study [20].
However, in this study, 44% of subjects were women, population with the single question was similar to a re-
cent report [32]. Our results provide support for theand 39% were on peritoneal dialysis.
In addition to chronic illnesses and medications, there use of the single question as a practical tool for large
population-based studies, where detailed clinical mea-are numerous reasons why patients with ESRD may
suffer from ED. Dialysis patients have lower testoster- sures of ED are impractical.
Despite having performed a population-based sam-one levels and have been shown to have suppression
of the pituitary testicular axis [21, 22]. Other proposed pling of male HD patients, our study, nonetheless, has
several limitations. Because the presence of ED andreasons for the high prevalence of ED among dialysis
patients include zinc deficiency [23, 24], hyperprolactin- associated conditions and exposures were assessed si-
multaneously, it was impossible to determine whetheremia [25], hyperparathyroidism [26], and psychological
conditions [13]. In an unadjusted analysis, higher mean we identified causal associations with ED. All of our
measures of ED were based on self-reporting, and nolevels of parathyroid hormone and creatinine were found
in patients without ED. These associations disappeared other physical or diagnostic tests were performed. We
attempted to standardize self-report of ED by using aafter adjustment for age and diabetes. The increased
mean creatinine value in the patients without ED may be questionnaire that has been validated in other settings
[4, 5, 33].a reflection of increased muscle mass in younger patients.
The use of ACEIs was significantly and inversely asso- When the interactions of race were examined with
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4. Rosen R, Cappelleri J, Smith M, et al: Development and evalua-the various other predictors, race did not modify the
tion of an abridged, 5-item, version of the IIEF as a diagnostic
association of any of other variable with ED when age tool for erectile dysfunction. Int J Impot Res 11:319–326, 1999
was included in the model. Thus, the associations we 5. Rosen RC, Riley A, Wagner G, et al: The International Index
of Erectile Function (IIEF): A multidimensional scale for assess-found between various predictors with ED should be
ment of erectile dysfunction. Urology 49:822–830, 1997generalizable to other populations with different race 6. Feldman HA, Goldstein I, Hatzichristou DG, et al: Impotence
compositions. and its medical and psychosocial correlates: Results of the Massa-
chusetts Male Aging Study. J Urol 151:54–61, 1994Although the 77.4% response rate in our study popula-
7. Karnofsky D, Burchenal J: The clinical evaluation of chemother-tion is generally considered good, we cannot exclude apeutic agents in cancer, in Evaluation of Chemotherapeutic Agents
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